Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Dual-Action pill tame the tumor behind cushing disease?

NCT ID NCT05971758

Recruiting now Disease control Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This phase 2 trial tests fimepinostat, a drug that blocks two cancer-related pathways, in adults with Cushing disease caused by a pituitary tumor. The goal is to see if the drug can lower cortisol levels to normal within four weeks. The study compares two doses and includes patients with new, persistent, or recurrent disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a drug called fimepinostat that blocks two tumor-related pathways (HDAC and PI3-kinase)
What this could lead to
If successful, this could offer a new non-surgical treatment option for Cushing disease by targeting the pituitary tumor directly.
What could go wrong
This is a small, early-phase pilot study with only 20 participants, so results may not apply broadly. The drug may cause side effects or fail to normalize cortisol levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUSHING DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ACTH-dependent Cushing syndrome Cushing disease due to pituitary adenoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUSHING DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ronald Reagan Medical Center

    RECRUITING

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.